vision is affected first, but eventually the entire vision will be lost if not treated. Diagnosis is made by looking for cupping of the optic nerve. Prostaglandin agonists work by opening uveoscleral passageways. Beta-blockers, such as timolol, work by decreasing aqueous formation. Carbonic anhydrase inhibitors decrease bicarbonate formation from ciliary processes in the eye, thus decreasing the formation of aqueous humor. Parasympathetic analogs are drugs that work on the trabecular outflow by opening up the passageway and constricting the pupil. Alpha 2 agonists (brimonidine, apraclonidine) both decrease fluid production (via inhibition of AC) and increase drainage. Developmental glaucoma Developmental glaucoma (Q15.0) Primary congenital glaucoma Infantile glaucoma Glaucoma associated with hereditary or familial diseases Secondary glaucoma Secondary glaucoma (H40.3-H40.6) Inflammatory glaucoma Uveitis of all types Fuchs heterochromic iridocyclitis Phacogenic glaucoma Angle-closure glaucoma with mature cataract Phacoanaphylactic glaucoma secondary to rupture of lens capsule Phacolytic glaucoma due to phacotoxic meshwork blockage Subluxation of lens Glaucoma secondary to intraocular hemorrhage Hyphema Hemolytic glaucoma, also known as erythroclastic glaucoma Traumatic glaucoma Angle recession glaucoma: Traumatic recession on anterior chamber angle Postsurgical glaucoma Aphakic pupillary block Ciliary block glaucoma Neovascular glaucoma (see below for more details) Drug-induced glaucoma Corticosteroid induced glaucoma Alpha-chymotrypsin glaucoma. Postoperative ocular hypertension from use of alpha chymotrypsin. Glaucoma of miscellaneous origin Associated with intraocular tumors Associated with retinal detachments Secondary to severe chemical burns of the eye Associated with essential iris atrophy Toxic glaucoma Neovascular glaucoma, an uncommon type of glaucoma, is difficult or nearly impossible to treat, and is often caused by proliferative diabetic retinopathy (PDR) or central retinal vein occlusion (CRVO). It may also be triggered by other conditions that result in ischemia of the retina or ciliary body. Individuals with poor blood flow to the eye are highly at risk for this condition. Neovascular glaucoma results when new, abnormal vessels begin developing in the angle of the eye that begin blocking the drainage. People with such condition begin to rapidly lose their eyesight. Sometimes, the disease appears very rapidly, especially after cataract surgery procedures. A new treatment for this disease, as first reported by Kahook and colleagues, involves the use of a novel group of medications known as anti-VEGF agents. These injectable medications can lead to a dramatic decrease in new vessel formation and, if injected early enough in the disease process, may lead to normalization of intraocular pressure. Currently, there are no high-quality controlled trials demonstrating a